Publications by authors named "Jim Biagi"

Claim this Profile
C
Characteristics of WT pancreatic adenocarcinomas: results of a large French multicentric cohort.
Noémie Trystram, Jérome Cros, Hélène Blons, Simon Garinet, Rémy Nicolle, Jim Biagi

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Vanessa Arciero, Jin Luo, Ambica Parmar, Wei Fang Dai, Jaclyn M Beca, Jim J Biagi

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter commenting on 'indications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic review'.
Rebecca Auer, Duvaraga Sivajohanathan, Jim Biagi, James Conner, Erin Kennedy

Eur J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Rebecca C Auer, Duvaraga Sivajohanathan, Jim Biagi, James Conner, Erin Kennedy

Eur J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators.
Andrés Enriquez, Jim Biagi, Damian Redfearn, Usama Boles, Dalia Kamel

JACC Clin Electrophysiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An organizational guideline for gynecologic oncology services.
Michael Fung-Kee-Fung, Erin B Kennedy, Jim Biagi, Terry Colgan, David D'Souza

Int J Gynecol Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Ivan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, Hal W Hirte, Stephen A Welch, Jim J Biagi

Gynecol Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Amit M Oza, Laurie Elit, Ming-Sound Tsao, Suzanne Kamel-Reid, Jim Biagi

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Amit M Oza, Elizabeth A Eisenhauer, Laurie Elit, Jean-Claude Cutz, Akira Sakurada, Jim Biagi

J Clin Oncol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis